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Abstract
Background: Pseudomonas aeruginosa encodes a putative topoisomerase with sequence similarity
to the eukaryotic type IB topoisomerase from Vaccinia virus. Residues in the active site are
conserved, notably Tyr292 which would be predicted to form the transient covalent bond to DNA.
Results: The gene encoding the P. aeruginosa topoisomerase I was cloned and expressed in E. coli.
The enzyme relaxes supercoiled DNA, while a mutant containing a Tyr292 to Phe substitution at
the active site was found to be catalytically inert. This is consistent with the role of Tyr in forming
the covalent intermediate. Like Vaccinia topoisomerase, the P. aeruginosa topoisomerase relaxes
DNA in the absence of ATP, but unlike Vaccinia topoisomerase, P. aeruginosa topoisomerase does
not relax supercoiled DNA without MgCl2 present. In addition, high concentration of NaCl is not
able to substitute for MgCl2 as seen for Vaccinia topoisomerase. A truncated derivative of the
topoisomerase lacking residues 1–98 relaxes DNA, with both full length and truncated enzyme
exhibiting equivalent requirements for divalent cations and the ability to relax DNA to completion,
suggesting a shared domain organization. DNA-binding assays suggest an only modest preference
for the CCCTT pentameric sequence required for transesterification by Vaccinia topoisomerase
IB.
Conclusion: P. aeruginosa encodes a functional topoisomerase with significant similarity to the
type IB enzyme encoded by poxviruses. In contrast to the Vaccinia-encoded homolog, the P.
aeruginosa-encoded enzyme requires divalent cations for catalytic activity, relaxes DNA to
completion, and does not exhibit a strong preference for the pentameric sequence stringently
required by the Vaccinia-encoded homolog. A comparison with the structure of poxviral
topoisomerase in complex with DNA suggests that bacterial homologs of the eukaryotic type IB
topoisomerase may exhibit a relaxed sequence preference due to the lack of conservation of
certain residues involved in sequence-specific DNA contacts, and that interaction with an only
modestly preferred sequence may result in suboptimal positioning of catalytic residues.
Background
DNA topoisomerases are enzymes that solve topological
problems associated with important processes such as
DNA replication, transcription, recombination and chro-
matin remodeling by introducing transient single or dou-
ble stranded breaks in the DNA and releasing
accumulated strain [1]. DNA cleavage leads to a transient
phosphodiester bond between a tyrosine at the active site
of the protein and one of the broken DNA strands. The
final step in the reaction is resealing of the DNA break, the
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topoisomerases are of two kinds; those enzymes that
cleave only one DNA strand are type I topoisomerases and
those enzymes that cleave both DNA strands are referred
to as type II. The type I topoisomerases are further classi-
fied as type IA or IB. In the type IA subfamily, the protein
is linked to the 5' phosphate and in the type IB subfamily,
the protein is linked to the 3' phosphate of the DNA sub-
strate [1]. The topoisomerases have attracted attention
precisely because of their diverse roles in controlling DNA
topology and therefore in regulating DNA-dependent
processes. They can act as potential targets for anticancer
drugs; for example, the plant alkaloid camptothecin
blocks DNA and RNA synthesis in the treated cells and
acts as an anticancer drug for human cancer by targeting
the topoisomerase I, causing accumulation of lethal DNA
strand breaks [2]. Coumermycin, which targets the Vac-
cinia topoisomerase, interferes with enzyme-DNA com-
plex formation [3]. Both the DNA topoisomerases and the
site-specific DNA recombinases perform cleavage and
ligation reactions [1,2,4-11]. Therefore, the topoisomer-
ases can also provide insight to the function of their close
cousins, the tyrosine recombinases, which could also
serve as drug targets.
Besides the linkage of the protein to either the 3'- or 5'-
end of the DNA, there is another difference in catalytic
mechanism between the type IA and type IB topoisomer-
ases. In reactions catalysed by the type IA enzymes, the
breaking of the duplex DNA and the rejoining event
occurring after the stress relief occurs in a single stranded
region of the DNA template [7,12,13]. This is in contrast
with the type IB topoisomerases, which generate a nick in
a double stranded region of the DNA template
[1,7,14,15]. The type IB topoisomerase might be able to
attack a single stranded region in a double stranded DNA
template but when such a reaction occurs the enzyme
might detach from the 5' end and yield a linear interme-
diate [1,16].
In contrast to the type I topoisomerases, the type II topoi-
somerases catalyze the breakage of both strands of DNA
and also catalyze the catenation and decatenation of dou-
ble stranded DNA circles [17-19]. The type II enzymes use
the energy released from ATP hydrolysis to create breaks
in the double stranded DNA, to cause the nearby double
helix to pass through this beak, to reseal the break and dis-
sociate the DNA [7]. By contrast, the type I enzymes do
not require ATP.
The eukaryotic type IB DNA topoisomerase family
includes the topoisomerase I encoded by the Vaccinia
virus [20,21]. It is the smallest topoisomerase known, a
314 amino acid protein that binds duplex DNA with strin-
gent specificity for transesterification at 5'-(C/T)CCTT
sites [15,21]. Indeed, all poxviruses studied encode a
topoisomerase IB homolog [22-26]. The Vaccinia virus
DNA topoisomerase I is biochemically similar to the
eukaryotic type I topoisomerase and yet is only one-third
the size. Proteins with homology to the Vaccinia topoi-
somerase IB are also encoded by a few eubacteria; for
example, the Pseudomonas aeruginosa topoisomerase I
(PAT) shares significant sequence similarity with Vaccinia
virus topoisomerase IB. The sizes of the bacterial enzymes
are similar to that of poxviral enzymes, and the tyrosine
nucleophiles as well as other residues implicated in catal-
ysis are well conserved. Therefore, the P. aeruginosa topoi-
somerase I can act as a model to study the mechanism of
topoisomerases as well as provide important insight into
the physiology of P. aeruginosa. A functional eubacterial
topoisomerase IB has so far only been described in Deino-
coccus radiodurans [27,28].
P. aeruginosa is a bacterium responsible for severe nosoco-
mial infections, life-threatening infections in immuno-
compromised persons, and chronic infections in cystic
fibrosis patients. The bacterium's virulence depends on a
large number of cell-associated and extracellular factors.
Considering that topoisomerases serve vital cellular func-
tions, the topoisomerase from this organism may be a
potential drug target as well [29]. In the present study, we
show that P. aeruginosa encodes a functional topoisomer-
ase I (PAT) with sequence similarity to the Vaccinia virus
and D. radiodurans topoisomerases IB. PAT requires Mg2+
for relaxation, but not ATP, and high concentration of
NaCl cannot substitute for Mg2+ in the reaction, unlike
what has been reported for the Vaccinia-encoded
homolog. A comparable domain organization and con-
stellation of catalytic residues is suggested by the observa-
tion that substitution of the tyrosine nucleophile in the
active site leads to a mutant that binds DNA but is unable
to relax DNA, and that the catalytic fragment is able to
relax supercoiled DNA in the absence of the N-terminal
domain.
Methods
Cloning and expression of P. aeruginosa topoisomerase I
The PAT gene was PCR amplified from the genomic DNA
UCBPP-PA14 using forward primer 5'-CGGAACCCACAT-
ATGAGCGCAGC-3' and reverse primer 5'-GCACGGCAT-
GGATCCGCACC-3'. NdeI and BamHI restriction sites
were incorporated into the oligonucleotide primers, and
the fragment containing the P. aeruginosa topoisomerase I
coding region was cloned into the E. coli expression vector
pET5a. The identity of the cloned fragment was confirmed
by DNA sequencing, and the recombinant plasmid was
used to transform E. coli strain BL21(DE3)pLysS. The
transformants were plated on MDAG media which is an
enriched, fully defined non-inducing media; the MDAG
media was prepared as described in [30], except the 1000×
metals was made according to [31]. Vaccinia topoisomer-
ase IB was purchased from Epicentre (Madison, WI).Page 2 of 13
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The point mutation on P. aeruginosa topoisomerase I to
replace the tyrosine with phenylalanine at the active site
was created using whole plasmid PCR. The sequence of
the forward primer is 5'-CGGCAATGCTTCATCCAC-
CCGG-3' and the reverse primer is 5'-GCA-
GATCGCCACGCTGTTGCC-3'. The template was
removed by DpnI digestion and the PCR product was used
to transform E. coli TOP10 (Invitrogen). The catalytic frag-
ment was created by amplification of the C-terminal
region using forward primer 5'-GCGCGAGCATATGGAT-
GCC-3' and reverse primer 5'-CCTTTCGTCTTCAAGAAT-
TCGGATCC-3'. NdeI and BamHI restriction sites were
introduced at either end of the PCR product, which was
cloned into pET5a. Constructs were confirmed by
sequencing.
Plasmids harboring the gene encoding the full length
enzyme (PAT), catalytic mutant (PATCAT) or the Y292F
mutant were transformed into BL21(DE3)pLysS, cells
were grown in LB media at 37°C, 250 rpm, until OD ≈ 0.2
and induced with Isopropyl β-D-1-thiogalactopyranoside
(IPTG) at a final concentration of 0.5 mM. After one hour,
the cells were harvested by pelleting and over-expression
was confirmed by SDS-PAGE followed by Coomassie Bril-
liant Blue staining. For PAT, Y292F and PATCAT the cells
were harvested by centrifugation and the pellets were
stored at -80°C. Due to instability of the PAT enzyme,
overexpression was also performed at room temperature,
but no difference was observed with regard to activity of
the purified protein.
Protein purification
Six 1500 ml cultures of E. coli BL21(DE3)pLysS contain-
ing plasmid carrying the PAT gene were induced as noted
above, cells were pelleted, and the pellet was redissolved
in HA buffer (50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 10%
glycerol and 0.25 M NaCl, 7.2 mM β-mercaptoethanol,
0.2 mM phenylmethylsulfonyl fluoride (PMSF)) and
lysed by sonication; about 20% P. aeruginosa topoisomer-
ase I was in the pellet at this step. After removing the insol-
uble material in the crude lysate by centrifugation at
5,000–6,000 rpm for 15 minutes, the soluble fractions
were subjected to 60% ammonium sulfate precipitation.
The supernatant remaining after the final precipitation
was found to contain 80% P. aeruginosa topoisomerase I.
The supernatant was dialyzed overnight against HA
buffer. The dialyzed supernatant was applied to a phos-
phocellulose column previously equilibrated to pH 8.0.
The elution was performed by applying a step gradient
from 0.4–1.5 M NaCl. All steps of purification were per-
formed at 0–4°C. The glycerol concentration in the eluate
was increased to 30% and the protein was stored at -20°C.
The pellet from the overexpressed Y292F mutant was dis-
solved in HA buffer and subjected to 30% ammonium
sulfate precipitation. The pellet from the precipitation was
redissolved in HA buffer, lysed by sonication and loaded
on a heparin agarose column in HA buffer. Protein was
eluted by a gradient from 0.4–1.5 M NaCl in HA. The
overexpressed PATCAT mutant was similarly subjected to
30% ammonium sulfate precipitation. The supernatant
from the precipitation was dialyzed against HA buffer
overnight and loaded onto the phosphocellulose column
pre-equilibrated in the same buffer. Protein was eluted by
step gradient from 0.4–1.5 M NaCl. Protein concentra-
tions were determined by Coomassie-stained SDS-PAGE
gels using BSA standards.
Relaxation assay
Relaxation assay (per 20 μl) was performed with nega-
tively supercoiled pUC18 DNA (≈ 110 ng) unless other-
wise stated, and the indicated amount of PAT in
topoisomerase buffer (50 mM Tris (pH 8.0), 2.5 mM
MgCl2, 0.1 mM EDTA) for two hours at 37°C. The reac-
tion also contained a final concentration of 0.24 M NaCl
and ≈ 19% glycerol from the protein storage buffer. Reac-
tions were stopped with 5 μl 1(10% SDS):1(30% glycerol)
stop buffer. The reactions were loaded on a 1% agarose gel
in 0.5× TBE buffer (45 mM Tris-borate (pH 8.3), 1 mM
EDTA). The gels were run at 2 V/cm for 16 hours. The gels
were stained with ethidium bromide (EtBr) and visualized
using an Alpha Innotech digital imaging System.
The positively supercoiled DNA was prepared by first
nicking pUC18 with N.BstNBI for an hour, followed by
phenol extraction and ethanol precipitation. Nicked
pUC18 was then incubated with netropsin and T4 DNA
ligase and again phenol extracted and ethanol precipi-
tated to remove the drug, resulting in the production of
positively supercoiled DNA. The production of positively
supercoiled DNA was confirmed by two dimensional aga-
rose gel electrophoresis, as described [32]. To confirm
production of covalently closed DNA on incubation with
PAT, the same reactions were electrophoresed both on 1%
agarose gels as noted above as well as on a gel containing
ethidium bromide.
Electrophoretic mobility shift assay
Oligonucleotides were purchased from Operon. The top
strand oligonucleotides were labeled at the 5' end with T4
polynucleotide kinase (New England Biolabs) and [γ-32P]
ATP and annealed to the bottom strand. The sequences of
the oligonucleotides are given in Table 1.
The reaction mixture per 20 μl contained 50 fmol of the
labeled DNA substrate which was incubated with the indi-
cated amount of P. aeruginosa topoisomerase I or mutant
protein in topoisomerase buffer (50 mM Tris (pH 8.0),
2.5 mM MgCl2, 0.1 mM EDTA) for one hour at 37°C. The
reaction mixture contained 0.67 M NaCl final concentra-
tion. The glycerol concentration in each sample wasPage 3 of 13
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instability of the protein, which precluded its concentra-
tion following elution. Samples were loaded on 8% (w/v)
PAGE (37:1 acrylamide/bisacrylamide) gels in 0.5 × TBE
and run for 90 minutes. Gels were visualized on a Molec-
ular Dynamics Storm Phosphoimager using software sup-
plied by the manufacturer.
Results
Sequence alignment
Screening of the NCBI database with the BLAST search
engine and PAT as the query yielded several homologs
including Vaccinia virus topoisomerase IB. A group of
conserved amino acid side chains in the active site coordi-
nate the attack of the tyrosine nucleophile on the scissile
phosphodiester. This catalytic pentad, Arg-130, Lys-167,
Lys-220, Arg-223 and His-265 as well as Tyr-274 for the
Vaccinia virus topoisomerase I, is conserved among the
poxvirus enzymes, while the closely related tyrosine
recombinases typically contain a histidine in place of the
lysine in position 220 of Vaccinia topoisomerase. The two
arginines and the histidine interact directly with the scis-
sile phosphodiester and may serve to stabilize a negatively
charged transition state [6,33-36]. The homologous resi-
dues in P. aeruginosa topoisomerase I are Arg-148, Lys-
185, Lys-247, Arg-250, Asn-283 and Tyr-292 (indicated
with an asterisk in Fig. 1) and in the D. radiodurans
encoded homolog, Arg-137, Lys-174, Lys-235, Arg-237,
Asn-280 and Tyr-289. The His-265 is replaced with Asn-
283 in P. aeruginosa topoisomerase and Asn-280 in D.
radiodurans topoisomerase[27]. The P. aeruginosa topoi-
somerase I showed 13% sequence identity with Ento-
mopox virus, 20% with Bovine Papular Stomatitis virus,
23% with Orf virus, 14% with Vaccinia virus IB, 14% with
Fowl Pox virus and the D. radiodurans topoisomerase
aligned particularly well at 36% identity. The C-terminal
catalytic domain is structurally conserved, and the cata-
lytic pentad occupies equivalent positions in the struc-
tures of the topoisomerases IB and tyrosine recombinases.
In contrast, the N-terminal domain is not conserved
between topoisomerases and recombinases.
The 333 amino acid P. aeruginosa topoisomerase I is pre-
dicted to consist of three protease-resistant structural
Table 1: The 37 bp DNA constructs.
A.37 bp VacSeq 5'-CGTGTCGATTCCGACGTCCCTTGCATTTATCAATTAT-3'
3'-GCACAGCTAAGGCTGCAGGGAACGTAAATAGTTAATA-5'
B.37 bp loops 5'-CCTAGGCTACACCTACTCTTTGTAAGAATTAAGCTTC-3'
3'-GGATCCGATGTGCTTGAGAAACAAACTTAATTCGAAG-5'
C.37 bp no loops 5'-CCTAGGCTACACCTACTCTTTGTAAGAATTAAGCTTC-3'
3'-GGATCCGATGTGGATGAGAAACATTCTTAATTCGAAG-5'
(A) The sequence of the 37 bp containing the Vaccinia recognition pentameric sequence in bold.(B) The sequence of the loop-containing duplex: 
the sequence of the bottom strand is modified to generate tandem mismatches of identical opposing nucleotides with spacing of 9 bp. The sequence 
generating the loops is in boldface.(C) The sequence of the perfect duplex without loops.
Sequence alignment of P. aeruginosa topoisomerase I with homologous topoisomeras s IBFig re 1
Sequence alignment of P. aeruginosa topoisomerase I 
with homologous topoisomerases IB. The amino acid 
sequences from Entomopoxvirus (MSV130), Bovine Papular 
Stomatitis virus (BPSVgORF062), Orf virus (ORFVgORF062), 
Vaccinia virus (H6R, Vaccinia topoisomerase type IB), Fowl 
Pox virus (FPV143) and D. radiodurans topoisomerase IB 
(DR_0690) are aligned with the P. aeruginosa topoisomerase I 
(PA2G_01347). Sequence gaps are indicated by dashes. The 
residues in blue and red correspond to identical and con-
served residues, respectively. The asterisks in black identify 
the conserved catalytic residues. The N-and C-terminal 
domains are demarcated by arrows.Page 4 of 13
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referred to as the bridge and the hinge (Fig. 2A) [37]. Res-
idues 1 through 98 constitute the N-terminal domain and
residues 99 through 333 are predicted to form the cata-
lytic C-terminal domain. The C-terminal domain, which
includes the bridge and the hinge also includes the active
site nucleophile (Tyr-292), which is implicated in transes-
terification. While the N-terminal domains of poxvirus
topoisomerases and tyrosine recombinases are divergent,
this domain is conserved between poxvirus and bacterial
topoisomerases. To establish whether the P. aeruginosa-
encoded homolog is functional, we cloned the gene and
characterized the purified protein. Based on sequence fea-
tures, we also created two mutants of PAT; one is the trun-
cated C-terminal domain consisting of residues 99–333
(PATCAT) and the other is the active site mutant where
the active site tyrosine nucleophile is changed to phenyla-
lanine, referred to here as Y292F. Initial expression analy-
ses of PAT revealed that the protein is highly unstable and
loses activity upon storage. For this reason, we performed
a relaxation assay each time before using the PAT for other
experiments. Under typical growth conditions, the pro-
tein was also toxic, and showed poor expression when
expressed using BL21(DE3)pLysS; therefore, the trans-
formants were grown on non-inducing media containing
low concentrations of glucose and amino acids. Glucose
and amino acids prevent induction by lactose during log
phase growth, and metabolic balancing of pH allowed
development of reliable non-inducing media. Expression
strains grown on non-inducing media retain plasmids and
Domain structure of P. aeruginosa topoisomerase IFigure 2
Domain structure of P. aeruginosa topoisomerase I. (A) Schematic representation of the tripartite structure predicted 
for the 333 amino acid P. aeruginosa topoisomerase I is illustrated using the Vaccinia topoisomerase IB as a template. The 
mutant protein lacking the 98-residue N-terminal domain is the catalytic fragment (PATCAT, residues 99–333). For the active 
site tyrosine mutant, the active site tyrosine is changed to phenylalanine (referred to as the Y292F mutant protein). (B) P. aer-
uginosa topoisomerase I wild type purified. The enzyme fraction was analyzed by SDS-PAGE. In lane 1 is the molecular weight 
marker, lane 2 shows the PAT. (C) P. aeruginosa topoisomerase I catalytic fragment purified, lane 1 shows the molecular 
marker and lane 2 shows the PATCAT (D) P. aeruginosa topoisomerase tyrosine mutant purified, lane 1 shows the molecular 
weight marker and lane 2 shows the Y292F mutant protein.Page 5 of 13
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comparable DNA binding sites for PAT and PATCAT may
be suggested by the observation that both proteins inter-
act strongly with phosphocellulose, the Y292F mutant
does not bind to the phosphocellulose and was instead
purified using heparin agarose chromatography. The puri-
fied wild type and mutant proteins are shown in Fig. 2B.
DNA relaxation activity of P. aeruginosa topoisomerase I
DNA relaxation activity of the P. aeruginosa topoisomerase
I enzyme was assayed by incubation with supercoiled
plasmid pUC18. Reaction mixtures containing freshly
prepared P. aeruginosa topoisomerase I and supercoiled
pUC18 were incubated for different times and the reac-
tions were terminated with SDS. The full-length enzyme
(9.2 ng) starts to relax 110 ng supercoiled pUC18 after 0.5
minutes and all the DNA is relaxed in 15 minutes; in com-
parison, the less efficient PATCAT (808.2 ng) starts to
relax 110 ng of supercoiled pUC18 after 0.5 min and the
DNA is completely relaxed in 15 minutes (Fig. 3A and
3B). For Vaccinia topoisomerase, 2.7 ng enzyme relaxes
300 ng supercoiled pUC18 in 0.25 min in the presence of
Mg2+ and in the absence of Mg2+ it relaxes DNA in 2 min-
utes [38]. The D. radiodurans topoisomerase IB is also not
as efficient as the Vaccinia homolog, about 350 ng
enzyme relaxes 300 ng of supercoiled pUC18 in 5 minutes
[27]. Consistent with its role in the transesterification
reaction, the Y292F mutant is unable to relax supercoiled
DNA (Fig. 3C). To determine if the product of PAT-medi-
ated DNA relaxation is covalently closed, reactions were
divided in two parts and one part electrophoresed on gels
containing ethidium bromide, under which conditions
only covalently closed DNA will become supercoiled. As
seen in Fig. 4, PAT does produce covalently closed product
(compare lanes 5). Quantitation of relative amounts of
relaxed and supercoiled DNA (lanes 5) show that the
majority of the supercoiled DNA seen in the presence of
ethidium bromide indeed corresponds to covalently
closed relaxed DNA that has become supercoiled in the
presence of ethidium bromide, and not residual super-
coiled DNA substrate. Note also that the mobility of DNA
that is supercoiled in the presence of ethidium bromide is
the same as that of the original substrate DNA, as evi-
denced by the observation that DNA relaxed by Vaccinia
topoisomerase IB likewise migrates to the same position
in the ethidium bromide-containing gel as the super-
coiled substrate DNA (panels C-D). We also note that the
fraction of nicked DNA appears to increase as the protein
preparation ages, reflecting instability of the enzyme.
Surprisingly, PAT is unable to relax DNA in the absence of
MgCl2 (Fig. 5). When titrating MgCl2 from 0 to 2.5 mM, P.
aeruginosa topoisomerase I (202 fmole) was seen to relax
supercoiled pUC18 DNA at 2.5 mM MgCl2. This is in con-
trast to Vaccinia topoisomerase I which was reported not
to require Mg2+ for activity although its activity is stimu-
lated in its presence [14]. DNA relaxation by P. aeruginosa
topoisomerase I with different salts in the reaction mix-
tures showed that the enzyme requires divalent cations for
relaxation, and that high concentration of NaCl cannot
substitute for MgCl2 in the reaction mixture. A more
detailed examination of the cation specificity is shown in
Fig. 6A–B. MgCl2, MnCl2, CuCl2 and ZnCl2 had a stimula-
tory effect on the relaxation activity. For Vaccinia topoi-
somerase I, higher concentration of monovalent salt can
substitute for MgCl2. By contrast, high concentration of
NaCl cannot substitute for MgCl2 in the reaction catalyzed
by PAT (Fig. 6C). Calcium and cobalt cannot substitute
for MgCl2 at relaxation of supercoiled DNA when com-
pared with zinc, copper, magnesium and manganese
(control reactions performed with metals only and no
(A) Kinetics of DNA relaxation by PATFigure 3
(A) Kinetics of DNA relaxation by PAT. Lane 1 shows 
relaxed DNA. Supercoiled pUC18 (110 ng) was relaxed with 
9 ng PAT in topoisomerase buffer. Lanes 2 through 10 con-
tain 110 ng of DNA and 9 ng PAT. Reactions were stopped 
after 0.5, 1, 2, 3, 4, 5, 10, 15 and 20 minutes. The relaxed 
DNA (R) and supercoiled DNA (S) are identified on the 
left.(B) Relaxation of supercoiled pUC18 in the presence of 
PATCAT. Lane 1 shows the relaxed DNA. The supercoiled 
pUC18 (110 ng) was relaxed with 9 ng PAT i. Lanes 2 
through 11 contain 110 ng DNA and 808.2 ng PATCAT. 
Reactions were stopped after 0.5, 1, 2, 3, 4, 5, 10, 15, 20, and 
25 minutes in lanes 2 to 11 respectively. The relaxed and 
supercoiled DNA are identified by (R) and (S) on the left. 
(C) The Y292F mutant is not able to relax supercoiled 
pUC18. The relaxed and supercoiled DNA are identified by 
(R) and (S) on the left. In lane 1, is shown the negative con-
trol containing supercoiled pUC18 and lane 2 is showing the 
relaxed DNA (supercoiled pUC18 (110 ng) relaxed with 
PAT (9 ng)). Lanes 3 through 7 contain 110 ng DNA and 241 
ng Y292F. Reactions were stopped after 5, 10, 15, 20 and 25 
minutes, respectively.Page 6 of 13
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aeruginosa topoisomerase I differs from Vaccinia virus
topoisomerase IB in the sense that Vaccinia virus topoi-
somerase IB does not relax DNA in the presence of ZnCl2
and for P. aeruginosa topoisomerase I, ZnCl2 is able to sub-
stitute for MgCl2 in the relaxation reaction (Fig. 6A, B)
[14]. PATCAT shares similar requirements for divalent cat-
ions as PAT (data not shown).
Vaccinia virus topoisomerase IB requires a monovalent
salt for relaxation activity and in the presence of EDTA the
activity was optimal between 100 and 250 mM NaCl [14].
This was not true for P. aeruginosa topoisomerase I which
fails to relax supercoiled DNA under comparable condi-
tions (Fig. 6C). High [NaCl] (1 M), however, was inhibi-
tory for enzyme activity (data not shown).
The type II topoisomerases utilize ATP for activity, while
the Type IA and IB topoisomerases do not require ATP to
relax DNA. Type I topoisomerases can thus be differenti-
ated from type II enzymes by either the requirement of
ATP or by the fact that the type I enzymes bring a change
in ± 1 in the linking number and type II change the linking
number by ± 2 [39]. As shown in Fig. 7, PAT does not
require ATP for relaxation, nor does ATP inhibit activity.
Eukaryotic type I topoisomerases differ from the prokary-
otic type I topoisomerase in the ability to relax positively
supercoiled DNA [40]. Indeed, Vaccinia topoisomerase IB
was reported to relax positively supercoiled DNA more
efficiently [41]. Notably, PAT is able to relax positively
supercoiled DNA (Fig. 8). We also note that the observed
activity is unlikely to derive from contaminating E. coli
topoisomerases; type II enzymes would be sensitive to
fluoroquinolone antibiotics (and yield a linear, not a
nicked intermediate), and the activity observed here is
insensitive to ciprofloxacin (data not shown). While con-
taminating Type IA activity may not be readily addressed
using inhibitors, such activity would be expected to result
in a population of topoisomers with different linking
numbers (e.g., [42]). Contaminating Tyr recombinases
are not likely either due to the observed requirement for
divalent metal ions for activity, indeed, contaminating
XerC/D recombinases can be ruled out, as plasmid pUC18
used for relaxation assays has no site for these site-specific
enzymes. As we consistently observe the generation of
covalently closed and nicked, relaxed species, we conclude
that the observed activity (which is absent in the prepara-
tions of Y292F and significantly reduced for PATCAT) is
PAT produces covalently closed, relaxed DNAFigure 4
PAT produces covalently closed, relaxed DNA. (A) 
Lane 1 contains the 1 Kb ladder, lane 2 contains 120 ng of 
supercoiled DNA, lane 3 contains 130 ng nicked DNA, lane 4 
contains 140 ng linear DNA and lane 5 contains 140 ng 
supercoiled pUC18 and 63 ng protein in topoisomerase 
buffer with MgCl2. The reaction mixtures were run on 1% 
agarose gel. (B) Lane 1 contains the 1 Kb ladder, lane 2 con-
tains 120 ng supercoiled DNA, lane 3 contains 130 ng nicked 
DNA, lane 4 contains 140 ng linear DNA, lane 5 contains 140 
ng supercoiled pUC18 and 63 ng protein in topoisomerase 
buffer with MgCl2. The reaction mixtures were run on a 1% 
agarose gel with 2 μg/ml ethidium bromide. Samples in panels 
A and B represent the same reaction, half of which is loaded 
on each gel. For reactions in lanes 5, quantitation of relative 
amounts of supercoiled DNA shows that <8% of total DNA 
remains supercoiled after incubation with topoisomerase 
(panel (A)), while ~35% of total DNA is supercoiled after 
electrophoresis in the presence of ethidium bromide (panel 
(B)), indicating that ~30% of total DNA is covalently closed 
following reaction with PAT. Panels (C) and (D) are equiva-
lent to (A) and (B) with lanes 2–5 containing supercoiled, lin-
ear, nicked, and relaxed DNA, respectively; DNA in lanes 5 
is relaxed with Vaccinia topoisomerase IB.
MgCl2 is required for DNA relaxationFi ure 5
MgCl2 is required for DNA relaxation. Lane 1 shows 
relaxed DNA (R) containing 110 ng pUC18 DNA and 9 ng 
PAT in topoisomerase buffer with 2.5 mM MgCl2 and lane 2 
shows supercoiled (S) DNA without PAT. Reaction mixtures 
containing 110 ng of supercoiled pUC18, 9 ng of PAT and 
increasing concentration of MgCl2, 0, 0.00025, 0.0025, 0.025, 
0.25, 2.5 mM in lanes 3–8, respectively.Page 7 of 13
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to completion following DNA strand incision.
Sequence preference of PAT
Vaccinia topoisomerase I is specific for cleavage of the
sequence (C/T)CCTT↓ in the scissile strand. To evaluate
the sequence preference of PAT, we therefore first com-
pared complex formation with 37 bp DNA containing the
Vaccinia topoisomerase recognition sequence, a 37 bp
DNA of average G+C content, or the equivalent 37 bp
DNA in which two 4 nucleotide loops were introduced
(Table 1). In addition, a previously published shorter
duplex used to monitor Vaccinia topoisomerase cleavage
kinetics was used; PAT does not yield a complex with this
18/24 duplex DNA used by the Vaccinia virus topoisomer-
ase IB (data not shown) perhaps because it is too short for
stable complex formation. However, PAT does bind the
37 bp DNA containing the pentameric Vaccinia sequence
and forms two complexes as seen in Fig. 9A. Some prefer-
ence for the CCCTT-containing DNA is suggested by the
observation that PAT does not form a discrete complex
with the 37 bp perfect duplex (Fig. 9B), but it does interact
more stably with the corresponding looped DNA (Fig.
10A). The Y292F mutant also binds DNA (37 bp looped
DNA Fig. 10B) but does not relax DNA. Regardless of
DNA substrate, the presence of MgCl2 in the reaction has
no effect on complex formation (data not shown).
The PAT forms two distinct complexes with 37 bp CCCTT-
containing DNA. It might be that the enzyme binds to the
DNA at different sites, thus giving rise to more than one
complex of distinct mobility. Maybe one PAT molecule
binds to CCCTT, which in turn causes a second PAT to
bind DNA, resulting in complexes that are stuck in the
well. The preferred binding to 37 bp DNA containing the
Vaccinia topoisomerase site suggests that PAT recognizes
certain sequence elements. While all poxvirus topoi-
somerases favor cleavage at (C/T)CCTT sequences [15],
surrounding sequences also effects DNA cleavage [43]; for
example, only four of the eight CCCTT sequences in
pUC19 are cleaved by MCV topoisomerase [26]. However,
the D. radiodurans encoded homolog was reported not to
share the preference for cleavage at (C/T)CCTT sites as evi-
denced by the failure to detect covalent adduct with
CCCTT-containing duplex DNA [27]. Similarly, we have
been unable to capture this covalent adduct using the 37
bp DNA (data not shown), reflecting either a lack of pref-
(A) Relaxation of supercoiled DNA in the presence of differ-ent cationsFigure 6
(A) Relaxation of supercoiled DNA in the presence of 
different cations. Reactions contained 200 ng of super-
coiled pUC18 and the indicated cation at 2.5 mM final con-
centration in topoisomerase buffer without MgCl2 and 0.24 
M NaCl. Lane 1: relaxed DNA (R); relaxation of 200 ng 
supercoiled pUC18 was performed with 9 ng of PAT in 
topoisomerase buffer with MgCl2 for 2 hours at 37°C. Lane 2 
contains 200 ng supercoiled pUC18 in the topoisomerase 
buffer indicated by (S) on the left hand side. Lanes 3 through 
6 contain 9 ng of PAT. (B) Reactions contain 75 ng of super-
coiled pUC18, 9 ng PAT, indicated cation at 2.5 mM concen-
tration. The relaxed DNA (R) and supercoiled pUC18 (S) are 
identified on the left and were obtained as described in (A). 
Control reactions with metals only and no enzyme reveal no 
nicking activity (data not shown). (C) Effect of NaCl on 
topoisomerase activity. Reaction mixtures contained 110 ng 
of supercoiled pUC18 DNA, 2.5 mM EDTA, 9 ng PAT, and 
increasing concentration of NaCl 265 mM, 290 mM, 315 mM, 
340 mM, 365 mM, 390 mM, 415 mM, 440 mM, 465 mM, 490 
mM, 540 mM and 590 mM in lanes 3 through 14 respectively 
in topoisomerase buffer without MgCl2. Lane 1 shows 
relaxed DNA and lane 2 is the supercoiled pUC18 DNA. 
The relaxed DNA (R) and supercoiled pUC18 (S) are identi-
fied on the left and were obtained as described in (A). Gels in 
panels (A) and (C) were electrophoresed at a higher voltage, 
reducing the separation between relaxed and supercoiled 
species.
PAT does not require ATP for relaxation of supercoiled DNAFigure 7
PAT does not require ATP for relaxation of super-
coiled DNA. All reactions contain 110 ng of supercoiled 
pUC18 and 9 ng of PAT. R indicates relaxed DNA and S indi-
cates supercoiled pUC18 in lane 1. Lane 2 contains 0.1 mM 
ATP and 0 mM MgCl2, lane 3 contains 1 mM ATP and 0 mM 
MgCl2, lane 4 contains 0.1 mM ATP and 0.25 mM MgCl2, lane 
5 contains 1 mM ATP and 0.25 mM MgCl2, lane 6 contains 
0.1 mM ATP and 2.5 mM MgCl2, lane 7 contains 1 mM ATP 
and 2.5 mM MgCl2.Page 8 of 13
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is too rapid to allow detection. For poxvirus-encoded
enzymes, such covalent adducts have been readily
detected; in contrast, for other topoisomerases, the cova-
lent intermediate is quite short-lived and generally cannot
be captured in absence of specific inhibitors or without
the use of suicide substrates in which the non-covalently
held DNA dissociates to prevent religation. That both bac-
terial topoisomerases fail to yield detectable covalent
intermediate suggest a mechanistic difference from poxvi-
rus-encoded homologs, either in terms of substrate recog-
nition or religation kinetics.
Discussion
Few bacterial species encode a type IB topoisomerase with
similarity to the poxvirus-encoded enzymes, and P. aerugi-
nosa topoisomerase I is only the second bacterial homolog
to be characterized and shown to be functional in vitro. The
structural gene for the P. aeruginosa topoisomerase I when
induced to express in E. coli results in the appearance of the
expected Mr 38 KDa polypeptide which is responsible for
the relaxation activity. While PAT relaxes both positively
and negatively supercoiled DNA in absence of ATP and
appears to retain the domain organization and constella-
tion of catalytic residues characteristic of the poxvirus-
encoded enzymes, PAT does exhibit a unique requirement
for divalent cations for catalytic activity.
PAT relaxes positively supercoiled DNA as well as negatively supercoiled DNAFigu  8
PAT relaxes positively supercoiled DNA as well as 
negatively supercoiled DNA. In lane 1 is positively super-
coiled pUC18 (S1), lane 2 contains negatively supercoiled 
pUC18 (S2), lane 3 contains positively supercoiled DNA 
relaxed, lane 4 contains negatively supercoiled DNA relaxed. 
Lanes 3 and 4 contain 110 ng of supercoiled DNA, 9 ng PAT 
in the topoisomerase buffer with 2.5 mM MgCl2.
Binding of PAT to 37 bp DNA with and without CCCTT-containing sequenceF gure 9
Binding of PAT to 37 bp DNA with and without 
CCCTT-containing sequence. (A) PAT 0, 20, 40, 68, 
136, 200, 268, 336, 400, 468, 712 fmol respectively in lanes 
1–11 in topoisomerase buffer with MgCl2. The glycerol con-
centration in lanes 1 through 11 varies from 8.34% to 24.5%. 
Free DNA (F), complex (C) and aggregates (A) are indicated 
on the right.(B) Binding of PAT to 37 bp perfect duplex 
DNA; PAT 0, 20, 40, 68, 136, 200, 268, 336, 400, 468, 712 
fmol respectively in lanes 1–11 in topoisomerase buffer with-
out MgCl2. The glycerol concentration varies from 8.34% to 
24.5% in lanes 1 through 11. Free DNA (F) and aggregates 
(A) are indicated on the right.Page 9 of 13
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Analysis of the purified enzyme showed that while PAT
does not require any divalent cation for DNA binding, it
does require divalent cations for relaxation of supercoiled
DNA, which suggests that either the divalent cations are
required for cleavage complex formation or for religation
of DNA after removal of the torsional strain. The divalent
cation could also play a role in site-specific binding,
including the enzyme's ability to discern the topological
state of the nucleic acid substrate. The poxvirus topoi-
somerases were reported not to require Mg2+ for binding
and cleavage, however, the Vaccinia enzyme activity is
stimulated 10- to 20-fold by divalent cations.
Domain organization of PAT
The catalytic fragment (235 amino acids) of P. aeruginosa
topoisomerase I lacking the amino terminal domain is
able to relax DNA, albeit less efficiently than the full-
length enzyme. Similarly, the Vaccinia topoisomerase cat-
alytic domain is less efficient than the full length enzyme,
a phenomenon ascribed to lower affinity binding to the
CCCTT target sequence and a reduced rate of DNA cleav-
age [38]. The structure of poxvirus topoisomerase IB in
complex with its cognate DNA site confirms the contribu-
tion of the N-terminal domain to site-specific binding
[44]. A β-strand from the N-terminal domain makes con-
tacts to several bases within the CCCTT sequence; these
residues (Tyr-70, Tyr-72 and Gln-69 of poxvirus topoi-
somerase) are all conserved in the P. aeruginosa-encoded
homolog. Thus, removal of the N-terminal domain of
PAT may likewise attenuate any sequence-preferences
exhibited by the full-length enzyme. Failure to engage the
cognate site adequately may in turn result in suboptimal
positioning of catalytic residues. Consistent with this
interpretation, mutation of Tyr-70, Tyr-72 and Gln-69 of
poxvirus topoisomerase results in defects in relaxation
activity [44].
The human topoisomerase (Fig. 11A) and the Deinococcus
topoisomerase have a preassembled cleavage site as
opposed to the Vaccinia virus topoisomerase in which the
active site is not preassembled prior to DNA binding (Fig.
11B) [8]. Comparison of the structures shows that three of
the Vaccinia topoisomerase catalytic residues, Arg-130,
Lys-167 and Tyr-274 are not in the correct position for
transesterification to occur [36,45]. A precleavage confor-
mational change in the catalytic domain would be neces-
sary to orient Tyr-274 to attack the scissile phosphate in
the DNA backbone [2,39,46], a conformational change
triggered by specific interaction with either strand of the
CCCTT target sequence [44]. Based on the sequence con-
servation between the bacterial enzymes and the proper-
ties of the Y292F mutant, we speculate that PAT may
likewise have a preassembled cleavage site. While the PAT
and PATCAT were both purified by chromatography on
phosphocellulose, the Y292F mutant did not bind to
phosphocellulose and was purified on the heparin col-
umn. If Y292F were far removed from the active site, its
replacement with Phe would be unlikely to alter features
of the active site. Therefore, we hypothesize that by chang-
ing the tyrosine at the active site, the cleavage site was
altered, resulting in attenuated interaction with the phos-
phocellulose column. That this alteration is likely subtle is
Binding of PAT and Y292F to 37 bp looped DNAF gure 10
Binding of PAT and Y292F to 37 bp looped DNA. (A) 
PAT 0, 20, 40, 68, 136, 200, 268, 336, 400, 468, 712 fmol 
respectively in lanes 1–11 in topoisomerase buffer with 
MgCl2 and 37 bp looped DNA. The glycerol concentration in 
lanes 1 through 11 varies from 8.34% to 24.5%. Free DNA 
(F), complex (C) and aggregates (A) are indicated on the left. 
(B) Binding of Y292F to 37 bp looped DNA. Y292F 0, 0.53, 
1.06, 1.8, 3.6, 5.3, 7.1, 8.9, 10.6, 12.4, 18.8 pmol respectively 
in lanes 1–11 in topoisomerase buffer with MgCl2 and 37 bp 
looped DNA. The glycerol concentration in lanes 1 through 
11 varies from 8.3% to 32.26%. Free DNA (F), complex (C) 
and aggregates (A) are indicated on the right.Page 10 of 13
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of wild type PAT and the Y292F mutant are comparable,
including preferred binding to CCCTT-containing and
looped DNA.
DNA binding by PAT
PAT binds to the 37 bp CCCTT-containing sequence as
opposed to little binding and no distinct complexes with
37 bp perfect duplex without this pentameric sequence.
Both N-and C-terminal domains of the poxviral enzymes
contribute to sequence-specific binding, and several resi-
dues involved in direct contacts are conserved, notably
Tyr-70 and Tyr-72 that contact the central CCT of the
CCCTT recognition sequence and Arg-80 and Lys-167 that
along with Tyr-72 contact the TT at the scissile phosphate;
Arg-80 is not conserved in the D. radiodurans-encoded
enzyme. However, Lys-133 which contacts the G opposite
the less stringently conserved 5'-C and contributes to posi-
tioning Arg-130 appropriately at the active site is not con-
served in the bacterial homologs, and neither is Asp-168
that makes a water-mediated contact to A at the scissile
phosphate [44]. It is therefore conceivable that the bacte-
rial enzymes exhibit only a modest preference for the
sequence stringently preferred by the poxviral enzyme.
PAT also binds 37 bp looped DNA; this could reflect a
binding mode similar to that of eukaryotic topoisomer-
ases which exhibit preferential binding to curved DNA
[47,48].
Human topoisomerase IB has an extensive network of
ionic contacts to the DNA [2]. These contacts are pro-
posed to restrict rotation of the non-covalently held DNA,
resulting in a "controlled rotation" event in which a single
superhelical turn is released per cleavage and religation
cycle. By contrast, Vaccinia topoisomerase IB releases an
average of five superhelical turns prior to religation, lead-
ing to the suggestion that non-covalently held DNA
rotates freely [49]. Considering the lack of conservation of
several residues seen to contact DNA in the poxviral
enzymes, it is conceivable that P. aeruginosa topoisomer-
ase releases superhelical turns in a completely unhindered
rotation event, the end result being complete DNA relaxa-
tion before religation can occur. That a significant amount
of nicked DNA is detected following DNA relaxation by
PAT may be a consequence of enzyme instability, as such
deleterious nicked products are unlikely to accumulate in
vivo. Alternatively, it is possible that PAT acts in concert
with other factors in vivo, resulting in suboptimal activity
in vitro; this phenomenon may indeed be related to the
observed complete relaxation of DNA if associated factors
serve to restrain non-covalently held DNA, thus aiding the
religation process. For PAT to exhibit recombinase activity
in vivo is less likely, however, considering the conservation
of the N-terminal domain, which is divergent for the oth-
erwise closely related Tyr recombinases but conserved
among poxviral and bacterial topoisomerase homologs.
The reactions catalyzed by PAT proceed via an intermedi-
ate in which there is a covalent linkage between the DNA
and the enzyme. Such complexes can generally be cap-
tured on denaturing gels, however, this complex has not
been captured for PAT. There could be several reasons for
this. PAT may exhibit a high degree of sequence preference
in selection of the cleavage site, a sequence preference
only partly emulated by the CCCTT sequence or its con-
text. Secondly, PAT might be recognizing not only
sequences but also certain structures in the DNA, perhaps
structures promoted by DNA supercoiling. Thirdly, the
reaction may be so fast that a suicide substrate needs to be
defined in order to capture the cleavage complex. Based
on the partial conservation of residues involved in
sequence specific DNA interactions we propose that bac-
terial type IB topoisomerases exhibit a relaxed sequence
preference, reflected in failure to capture a cleavage com-
plex with CCCTT-containing DNA and a reduced relaxa-
tion activity compared to the poxviral enzymes.
Conclusion
P. aeruginosa encodes a type I topoisomerase with
sequence and biochemical characteristics similar to those
In the figure is shown the cleavage site assembly for the human topoisomerase (PDB IK4T) (panel A) and Vaccinia topoisomera e IB (PDB IA4I) (panel B)Figure 11
In the figure is shown the cleavage site assembly for 
the human topoisomerase (PDB IK4T) (panel A) and 
Vaccinia topoisomerase IB (PDB IA4I) (panel B). The 
human topoisomerase IB has a preassembled precleavage site 
but in the Vaccinia enzyme, the catalytic tyrosine is located 
away from the cleavage site and is reoriented after DNA 
binding.Page 11 of 13
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ization resembles that of Vaccinia topoisomerase IB in
that residues in the active site are conserved, and a trun-
cated variant lacking the N-terminal domain retains cata-
lytic activity, albeit with lower efficiency compared to the
full-length enzyme. In contrast to the Vaccinia-encoded
homolog, the P. aeruginosa-encoded enzyme requires
divalent cations for catalytic activity, relaxes DNA to com-
pletion, and shows an only modest preference for the
CCCTT pentameric sequence required for transesterifica-
tion by Vaccinia topoisomerase IB. Analysis of the
sequence and structural information suggests that the bac-
terial topoisomerases IB exhibit reduced activity com-
pared to the poxviral enzymes due to lack of conservation
of residues required for optimal positioning of catalytic
residues.
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